Applications of Halofantrine Hydrochloride in Industrial Manufacturing

As a committed manufacturer of Halofantrine Hydrochloride, we supply this essential antimalarial active ingredient for pharmaceutical production. Our focus lies in quality consistency, regulatory support, and tailor-made specifications for solid dosage manufacturers worldwide. Below, we outline key real-world industrial applications where our raw material plays a critical role, including downstream compliance standards, integration steps, formulation guidance, and finished product types.

1. Oral Solid Antimalarial Drug Formulations

Large-scale pharmaceutical companies formulate halofantrine hydrochloride into solid dosage forms, including tablets and capsules. Manufacturers follow strict compliance with international pharmacopoeias and regulatory agencies to ensure therapeutic performance and patient safety. During granulation, precise metering of the API must be ensured to maintain dose uniformity, taking API load, tablet weight, and excipient compatibility into account.

Industry compliance standards

• USP (United States Pharmacopeia)
• Ph. Eur. (European Pharmacopoeia)
• International Conference on Harmonisation (ICH) Q7 GMP Guidelines
• Current Good Manufacturing Practice (cGMP) as enforced by FDA and EMA

Typical usage ratio

• 30–50 mg per tablet (final film-coated or uncoated dosage), adjusted based on product market, end-user demographic, and local regulatory dose limitations
• API forms 2–8% w/w of tablet core blend

Downstream process integration

• Incorporated during high-shear wet granulation or direct blending prior to compaction
• Sifted alongside lactose or microcrystalline cellulose fillers and disintegrants, followed by lubrication with magnesium stearate
• Blending and tableting performed in controlled humidity environments, then optional film-coating

Final product types

• Halofantrine Hydrochloride 250 mg tablets (strip-pack or blister-pack)
• Oral capsules for hospital and retail markets
• Ready-to-dispense unit dose pharmacy packs

2. Pediatric Granule and Suspension Manufacturing

Pediatric pharmaceutical divisions formulate halofantrine hydrochloride into granules and suspensions designed for child-friendly dosing. Manufacturers must comply with pediatric-specific regulatory standards on excipients, taste-masking, and safety assessments. The API is processed into fine granules or suspended in sorbitol-based syrups for accurate and palatable administration.

Industry compliance standards

• WHO Prequalification Guidelines for Antimalarial Medicines
• PIC/S GMP Guide
• Ph. Int. (International Pharmacopoeia, WHO)
• EMA “Guideline on Pharmaceutical Development of Medicines for Paediatric Use”

Typical usage ratio

• Oral suspension: 40–60 mg per 5 mL dose, equating to 0.8–1.2% API w/v in bottle fill volume
• Granule sachets: 25–30 mg API per sachet, adjusting load for body weight-based dosing protocols

Downstream process integration

• API pre-mixed with sweeteners and stabilizers in a ribbon blender; granulation performed with water/alcohol for pediatric granules
• For suspensions, wet-milling with hydrocolloid thickeners and flavorants prior to bottling under nitrogen atmosphere
• In-process controls for sedimentation rate and particle size uniformity

Final product types

• Sugar-free oral suspension bottles for pediatric prescriptions
• Pediatric dry granule single-dose sachets
• Unit-dose granule sticks for low-resource settings

3. Bulk Pharmaceutical Ingredient Supply for Licensed Repackaging

Licensed repackaging and compounding facilities source halofantrine hydrochloride in API bulk for customized product batch preparation. These downstream users operate under strict audit and traceability obligations, requiring full analytical dossier and transportation under GDP conditions. Bulk material is repackaged into single-use containers or compounded into unit doses by hospital pharmacy teams.

Industry compliance standards

• EU GDP (Good Distribution Practice)
• WHO Model Certificate of Pharmaceutical Product (CPP)
• 21 CFR 210/211 (US FDA)
• Pharmacopeial monograph testing (assay, purity, residual solvents, particle size)

Typical usage ratio

• Batches repackaged into 0.5–5 kg containers for hospital or central pharmacy use
• Compounded oral suspensions: 0.02–0.1% API w/v, according to local magistral formulae

Downstream process integration

• Received bulk API sieved under laminar airflow and vacuum-transferred to compounding stations
• Repackaging in despersible bags under class 100,000 clean area
• Compounding performed by trained pharmacists following master batch records

Final product types

• Single-use API portion vials for extemporaneous use
• Customized hospital compounding kits
• Bulk master lots for redistribution to authorized regional health authorities

4. Combination Antimalarial Drug Development

Innovator and generic pharmaceutical R&D teams employ halofantrine hydrochloride as a key component in fixed-dose combination antimalarial research. Regulatory focus here covers both active substance compatibility and clinical protocol support. The API undergoes various analytical studies, including compatibility trials with standard partner drugs to formulate co-administered and dual-layer tablets with synchronized release profiles.

Industry compliance standards

• ICH Q3A/B/C (Impurities, Residual Solvents, Stability)
• Guideline on Fixed Combination Products (ICH M13, FDA, EMA)
• National Medicines Regulatory Authority (NMRA) dossier requirements
• Ph. Int. and relevant national pharmacopoeial methods for FDCs

Typical usage ratio

• API incorporated at 20–35 mg per unit for experimental low-dose combination tablets, jointly with other approved antimalarials
• API proportion tailored to clinical trial phase, bioequivalence studies, and partner drug selection

Downstream process integration

• Direct blending or bilayer tablet compression using twin-screw feeders for phase one to phase three clinical manufacturing
• API performance verified via dissolution profiling and forced degradation trials in paired matrices
• Downstream packaging in small clinical trial sample packs with serialized labelling

Final product types

• Pilot-scale fixed-dose combination antimalarial tablets
• Clinical batch co-packaged blisters for regulator-authorized studies
• Reference standards for bioequivalence trial use